Trials / Completed
CompletedNCT02825420
Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients
NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 220 (actual)
- Sponsor
- PharmaMar · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional, multicenter, prospective, European study to describe the effectiveness of trabectedin + PLD in the treatment of relapsed ovarian cancer (ROC) patients according to SmPC regardless of previous use of an antiangiogenic drug
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | trabectedin |
Timeline
- Start date
- 2015-07-28
- Primary completion
- 2019-09-18
- Completion
- 2019-09-18
- First posted
- 2016-07-07
- Last updated
- 2021-10-29
- Results posted
- 2021-10-29
Locations
65 sites across 5 countries: Belgium, France, Germany, Italy, Spain
Source: ClinicalTrials.gov record NCT02825420. Inclusion in this directory is not an endorsement.